Guest guest Posted March 9, 2008 Report Share Posted March 9, 2008 Hi all, The journal blood has an article in the last issue on the long term effects of gleevec on bone formation. From what I read and was able to understand (I am no md) gleevec has definitively an impact on our bones, but it may not be the way we usually thought. It looks it may actually increase bone density, they even suggest it could be used to treat osteoporosis. They do encourage drs treating cml patients to monitor bone health. Here an extract from the conclusion : " In summary, we demonstrate for the first time that imatinib mesylate significantly modulates bone turnover, as evidenced by an increase in TBV and lowered levels of serum calcium and phosphate. Although we are unable to predict the long-term skeletal consequences of this drug, our study does suggest that patient management and care should include appropriate monitoring of skeletal health. Furthermore, the observed increase in TBV, a significant determinant of bone strength, raises the intriguing possibility that imatinib and similar agents may have uses in treating diseases that are characterized by generalized bone loss, such as osteoporosis and osteomalacia. This possibility is particularly attractive in light of the long-term safety data that have accrued during imatinib's widespread use as a front-line therapy for CML and GIST. " The link is : http://bloodjournal.hematologylibrary.org/cgi/content/full/111/5/2538 Marcos. PS: No snow here, forecast for tomorrow is sun and temperature in the 70s -- Marcos Perreau Guimaraes Suppes Brain Lab Ventura Hall - CSLI Stanford University 220 Panama street Stanford CA 94305-4101 650 614 2305 650 630 5015 (cell) marcospg@... montereyunderwater@... www.stanford.edu/~marcospg/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.